https://cdn.specpick.com/images/gophotonics/seminex_lsr_wrld_wall.jpg712370
SemiNex Corporation has unveiled its new laser with 1270 nm wavelength for the first time at this year’s World of Photonics show in Munich. The new wavelength builds upon SemiNex’s prior range of 1300 - 1700 nm and expands the company into new areas of the medical industry.
SemiNex teamed up with Veralase, and Massachusetts General Hospital to develop an affordable hand-held laser device that operates at 1270 nm. This specific wavelength has proven to enhance immune response to vaccines. The near-infrared laser treatment avoids side effects like soreness, inflammation, erythema and tissue damage that often occurs with chemical adjuvants. Under a U.S. National Institute of Health (NIH) grant received by Veralase, SemiNex continues to support the research of other optimal wavelengths and their potential clinical applications.
Another remarkable use for 1270 nm is in creating different forms of oxygen. 1270 nm irradiation in water causes photo-activation in the ground state of oxygen to create singlet oxygen which is a high energy form of oxygen that can be used in preparative organic chemistry and photodynamic therapy. The uses for singlet oxygen continues to be explored. 1270 nm laser diodes set a new record at SemiNex for the highest powers and efficiencies to date.
These added benefits of power and efficiency will enable customers to use small, efficient and relatively inexpensive laser diodes to develop products in many industries and applications. Continuous improvement is a core value at SemiNex and the company plans to develop and fine-tune the new wavelength in response to customer and market needs. SemiNex is proud to be a part of improving worldwide healthcare and anticipates taking on new medical projects in the near future.